Johnson & Johnson (NYSE: JNJ) has become a colossus in the healthcare industry with its exposure to the pharmaceutical, medical device, and consumer over-the-counter health-products markets combining to make the company a force to be reckoned with. Yet although the stock performed well in 2016, gaining 15% for the year, J&J shares lost ground in the second half of the year. Now, some investors are worried that harsher drug-pricing regulations could eat into profits in what has been J&J’s biggest source of growth recently.